FDA unveils new guidance extending postmarket safety regulations on some combo products | FierceBiotech
Mar 21, 2018 @ 11:57

The FDA set into place two new guidelines for device and drug makers that address a final rule from its 2016 postmarketing safety reporting requirements for combination treatments that involve a drug, device and/or biological product.

Sourced through Scoop.it from: www.fiercebiotech.com

Leave a Reply